← Back to Search

SpeechVive for Parkinson's Disease

N/A

Waitlist Available

Led By Kelly Richardson, Ph.D.

Research Sponsored by University of Massachusetts, Amherst

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up change from baseline after 8 weeks of treatment

Awards & highlights

No Placebo-Only Group

Summary

This trial tests two treatments, LSVT LOUD and SpeechVive, to help people with Parkinson's disease speak louder. LSVT LOUD teaches self-monitoring of voice, while SpeechVive uses an ear device to prompt louder speech. The study aims to understand how these treatments affect breathing and voice control, and how easy they are for patients to use. LSVT LOUD is an intensive program devised in the United States to train patients with Parkinson's disease to speak louder, at normal intensity, while keeping a good voice quality.

Eligible Conditions

Parkinson's Disease

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ change from baseline after 8 weeks of treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~change from baseline after 8 weeks of treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline after 8 weeks of treatment for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Assessing Mental and Physical Effort Associated With Each Treatment Program Using the Modified National Aeronautics and Space Administration (NASA)-Task Load Index

Treatment-related Changes in Speech Breathing Will be Assessed Using Laryngeal Aerodynamics (MFDR)

Treatment-related Changes in Speech Breathing Will be Assessed Using Laryngeal Aerodynamics (Open Quotient)

+2 more

Secondary study objectives

Treatment-related Changes in Activities of Daily Living Assessed by the Voice-related Quality of Life (VR-QOL) Questionnaire

Treatment-related Changes in Communicative Competence Will be Assessed Using the Communicative Participation Item Bank-Short Form Questionnaire

Treatment-related Changes in Quality of Life Will be Assessed Using the Parkinson's Disease Questionnaire (PDQ-39)

+2 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: SpeechViveExperimental Treatment1 Intervention

Persons with Parkinson's disease receive eight weeks of voice treatment using the SpeechVive device.

Group II: Lee Silverman Voice TreatmentExperimental Treatment1 Intervention

Persons with Parkinson's disease receive Lee Silverman Voice Treatment over an eight week period. Four weeks of face-to-face intervention and four weeks of home practice.

Group III: ControlActive Control1 Intervention

Persons with Parkinsons disease do not receive voice intervention

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Lee Silverman Voice Treatment

2018

N/A

~40

SpeechVive

2018